Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24455553 | 1.00 | FOLH1 (0.44) | FOLH1TACR1CTSBCTSSMEN1 | |
| SCHEMBL26222813 | 0.93 | FOLH1 (0.48) | FOLH1CTSBCTSSMEN1ALDH1A1 | |
| SCHEMBL29678852 | 0.93 | FOLH1 (0.48) | FOLH1CTSBCTSSMEN1ALDH1A1 | |
| SCHEMBL29008427 | 0.93 | FOLH1 (0.48) | FOLH1CTSBCTSSMEN1ALDH1A1 | |
| SCHEMBL29678991 | 0.93 | FOLH1 (0.48) | FOLH1CTSBCTSSMEN1ALDH1A1 | |
| SCHEMBL22878180 | 0.91 | FOLH1 (0.46) | FOLH1CTSBCTSSCTSKTGM2 | |
| SCHEMBL25963739 | 0.91 | FOLH1 (0.46) | FOLH1CTSBCTSSCTSKTGM2 | |
| SCHEMBL29679161 | 0.88 | TDP1 (0.42) | TGM2 | |
| SCHEMBL29335966 | 0.86 | FOLH1 (0.51) | FOLH1CTSBCTSSCTSKCTSL | |
| SCHEMBL30971350 | 0.86 | FOLH1 (0.51) | FOLH1CTSBCTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025866-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | NOVARTIS AG (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20240025866-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | NOVARTIS AG (CH) | 2024-01-25 | — | — | US | disclosed |
| WO-2022106629-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | NOVARTIS AG (CH) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025866-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | FOLH1, KLK3, BPHL | FOLH1 1/4885TACR1 1067/4885CTSB 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.